[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Getz Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":198},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,78,107,130,148,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100644912","faisalabad-initiative-of-research-and-management-of-ncds-100644912",false,"NCT07676214","Faisalabad Initiative of Research and Management of NCDs","FIRM-NCD","Inclusion Criteria:\n\nAge: 18 years and above Gender: Both male and female Permanent residents of the selected study areas Willing to participate and provide informed consent\n\nExclusion Criteria:\n\nPregnant and lactating women Oral and injectable contraceptive users Individuals with severe physical or cognitive impairments that prevent them from providing informed consent or participating in the screening procedures Individuals with implanted electronic medical devices (e.g., pacemakers or implantable cardioverter-defibrillators) will not undergo bioelectrical impedance analysis (BIA) for body composition assessment.",true,"ALL","18 Years",{"count":20,"type":21},3000,"ESTIMATED","3 Months","OBSERVATIONAL","The burden of noncommunicable diseases (NCDs) continues to rise globally, and they have become the leading cause of morbidity and mortality, accounting for over 70% of deaths worldwide¹. Rapid lifestyle transitions and increasing urbanization have disproportionately affected low- and middle-income countries, which now bear a substantial share of the global NCD burden.\n\nPakistan, with a population of 241.5 million, is experiencing a double burden of both communicable diseases and NCDs¹³. The widespread adoption of sedentary lifestyles and unhealthy dietary patterns has contributed to a marked increase in NCDs across the country².\n\nAccording to the WHO Hypertension profile 2025, it is the most prevalent NCD in Pakistan, affecting approximately 42% (41% males and 44% females) of the population¹¹, followed by diabetes, with a reported prevalence of 30.8%¹². Additionally, a recent cross-sectional study among adults attending a tertiary care hospital in Islamabad reported dyslipidemia in 71.6% of men and 78.4% of women, indicating a substantial underlying community burden³. Pakistan also ranks tenth among 188 countries in terms of overweight and obesity prevalence, with nearly half of its population classified as overweight or obese⁴. According to World Health Organization data, 58.1% of Pakistanis are overweight, and 43.9% fall within the obese category⁴.\n\nDespite their profound public health and economic implications, efforts to address NCDs remain fragmented and insufficient.17 There remains a significant research gap in community-based NCD screening initiatives, particularly within the suburban and peri-urban communities of Faisalabad creating an unmet need to initiate a preventive strategy at community level to raise awareness about these diseases. This direction will minimize the increasing incidence and prevalence of NCDs and will ensure the quality health outcomes for better future.\n\nTimely identification of these diseases through screening is a critical step in reducing their impact on individuals and societies. Early detection enables cost-effective management, improved patient outcomes and a higher quality of life.14 One of the most important ways of reducing deaths from noncommunicable diseases (NCDs) is to control the risk factors that lead to their development.6 In this context, the present study aims to evaluate a community-based project focusing on disease awareness, screening, and structured referral to trained treating physicians for early diagnosis and management of major NCDs. The findings are expected to inform scalable, evidence-based interventions to reduce NCD burden and improve population health outcomes in Pakistan.",[26,27,28,29],"Diabete Mellitus","Hypertension","Hypercholerolemia","Obesity (Disorder)",[31,32,27,33,34],"community screening","Diabetes","Obesity","Hypercholestrolemia","NOT_YET_RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":21},"2026-08-01",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Getz Pharma","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100637631","cgm-experience-preferences--blood-glucose-parameters-100637631","NCT07607015","CGM Experience, Preferences & Blood Glucose Parameters","Instara™-1 Dual Perspectives on Continuous Glucose Monitoring: Understanding Patient Experience and Healthcare Professional Preferences","Inclusion Criteria:\n\n* Subjects to provide written informed consent prior to any study procedures being performed\n* Subjects with age 18 and above both male and female\n* Diagnosed with Diabetes Miletus Type I, Type II and\u002For GDM\n* Comfortable using smart phone, access to internet along with Bluetooth connectivity throughout the study duration.\n* Subjects (Patients) on oral or injectable anti-diabetic medications, (in case of insulin, patient must be on insulin from last 3 months )\n* Subjects (HCPs) healthy, Pre-diabetes or Diabetes Miletus (any type)\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the active or inactive ingredients of the CGM device used in the trial, and\u002For history of significant allergic skin reactions.\n* Presence of severe diabetes complications e.g. retinopathy, acute metabolic crisis, etc.\n* History of active\u002F acute renal and\u002For hepatic failure.\n* Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state.\n* History of critical illness or incapacitated patients\n* History of acute psychiatric disorder or exacerbation of chronic psychiatric disorder.\n* History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study.\n* Medical conditions that require patients to undergo frequent radiation\u002F imaging procedures for example CT, MRI and X rays\n* History of known hematological disorders such as Sickle Cell Disease \\& Trait, Thalassemia, Hemolytic Anemias (e.g., G6PD deficiency, autoimmune), Iron Deficiency Anemia\n* Patients on high doses of acetaminophen (\\>1 gram every 6 hours), ascorbic acid supplements (e.g., \\> 500-1000 mg\u002Fday), IV sorbitol, steroids and aspirin which can alter the readings on the CGM device.",{"count":55,"type":21},75,"This is an open-label, prospective, multicenter observational study designed to evaluate the perceived benefits, device experience, preference, and glucose-related parameters associated with the Instara-1 Continuous Glucose Monitoring device. The study will include patients with diabetes and healthcare professionals. Patients will use Instara- 1 and will be followed up to assess device experience, glucose parameters, and diabetes-related quality of life. Healthcare professionals will evaluate device experience and preference, including comparison with FreeStyle Libre 2.",[26,58,59,60,61],"Type2diabetes","type1diabetes","Gestational Diabetes","Pre Diabetes",[63,64,65,66,67,68,69],"CGM","Glucose monitoring","Time in range","estimated HbA1c","Time above range","Time below range","Diabetes Quality of life","2026-05-19",{"date":72,"type":39},"2026-05-26",{"date":74,"type":21},"2026-09-10",{"date":76,"type":21},"2027-08-10",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100451881","phase-4-real-world-safety--efficacy-experience-of-empagliflozin-with-or-without-metformin-in-t2dm-patients---ease-study-100451881","NCT05164263","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus","EASE","Inclusion Criteria:\n\nPatient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL\u002Fmin\u002F1.73m2.\n\nExclusion Criteria:\n\nType 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and\u002For hepatic dysfunctions, where RFT and Urine R\u002FE is abnormal, Diabetic Ketoacidosis and\u002For hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.","65 Years",{"count":88,"type":21},2000,"INTERVENTIONAL",[91],"PHASE4","Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.\n\nStudy design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.\n\nSample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).\n\nFollow up visits: After recruitment, patient is supposed to have three visits for follow-ups.\n\nVisit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.\n\nLABORATORY TESTING:\n\nReputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R\u002FE. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.\n\nWhere in Urine Routine Examination (Urine R\u002FE), we consider as follows:\n\n* Visual Examination:\n\n  * Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.\n  * Urine clarity: Clear, slightly Cloudy, cloudy or turbidity\n* Chemical Examination:\n\n  * Specific gravity\n  * pH\n  * Bilirubin\n  * Urobilinogen\n  * Protein\n  * Ketone\n  * Leukocyte Esterase\n* Microscopic Examination:\n\n  * Red Blood Cells:\n  * Epithelial Cells:\n  * Amorphous:\n  * Pus Cells\n  * Bacteria\n  * Yeast\n  * Casts\n  * Crystals\n\nWhere in Renal Function Test (RFT), we consider as follows:\n\n* Blood Urea Nitrogen (BUN): mg\u002FdL\n* Serum Creatinine: mg\u002FdL\n* Estimated Glomerular Filtration Rate (eGFR): mL\u002Fmin\u002F1.73 m2",[94,95,96],"Type II Diabetes Mellitus","Efficacy, Self","Safety Issues","RECRUITING","2026-01-20",{"date":100,"type":39},"2026-01-22",{"date":102,"type":39},"2021-04-01",{"date":104,"type":21},"2027-08-31",{"name":45,"class":46},6,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":89,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100606341","phase-3-acotiamide-vs-itopride-in-postprandial-distress-syndrome-100606341","NCT07174297","Acotiamide vs Itopride in Postprandial Distress Syndrome","To Compare the Efficacy and Safety of Acotiamide Versus Itopride in Patient With Post Prandial Distress Syndrome Type of Functional Dyspepsia","Inclusion Criteria:\n\n* Subjects to provide written informed consent prior to any study procedures being performed\n* Subjects with age 18-70 both male and female\n* Diagnosed with FD (PDS) by using ROME IV criteria\n* Subjects naive to acotiamide and Itopride for last 2 weeks\n* Subjects must have a normal endoscopy result within the 6 months\n\nExclusion Criteria:\n\n* Without predominant symptoms of ulcer and GERD based on history \\& endoscopy, IBS based on history \\& Rome IV criteria and Chronic idiopathic nausea based on history only\n* Subjects taking drugs that affect gut motility, gut sensitivity, SSRI and\u002For acid secretion who are unable to discontinue these drugs before initiating the intervention\n* Subjects with chronic medical disorders potentially contributing to PDS such as chronic pancreatitis, hypothyroidism, CKD and CLD identified through clinical history, physical examination, or previous medical records\n* Subjects with Type I or Type II diabetes\n* Pregnant \\& lactating mothers","70 Years",{"count":116,"type":21},152,[118],"PHASE3","The goal of this study is to \"To compare the efficacy and safety of Acotiamide versus Itopride in patient with post prandial distress syndrome type of functional dyspepsia\"",[121],"Postprandial Distress Syndrome","2025-09-18",{"date":124,"type":39},"2025-09-23",{"date":126,"type":21},"2025-10-30",{"date":128,"type":21},"2027-04-30",{"name":45,"class":46},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100595337","diabetes-foot-africa-region-registry-100595337","NCT07031141","Diabetes Foot Africa Region Registry","(D-FAR)","Inclusion Criteria:\n\n1. Male and female patients\n2. Residents of participating African countries.\n3. Diagnosed with diabetic foot complications (e.g., ulcers, gangrene, infection, ischemia).\n4. Patients with a history of foot ulcers or amputations due to diabetes.\n5. High-risk patients with peripheral neuropathy and\u002For peripheral arterial disease.\n\nExclusion Criteria:\n\n1. Non-diabetic foot complications.\n2. Acute traumatic injuries unrelated to diabetes.\n3. Patients unwilling to provide informed consent.",{"count":88,"type":21},"D-FAR is to gather robust data on the clinical characteristics, management, and outcomes of patients with diabetic foot complications to enhance understanding, reduce complications, and improve patient care. This will include insights into the prevalence of risk factors, adherence to treatment protocols, and the effectiveness of interventions aimed at reducing the incidence of amputations and other adverse outcomes.",[32],"2025-06-12",{"date":142,"type":39},"2025-06-22",{"date":144,"type":21},"2025-08-01",{"date":146,"type":21},"2027-02-01",{"name":45,"class":46},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":156,"targetDuration":4,"studyType":89,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100488792","phase-4-effect-of-erugliflozin-on-liver-fat-liver-fibrosis-and-glycemic-control-in-type-ii-dm-patients-with-nashnafld-100488792","NCT05644717","Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH\u002FNAFLD","Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease \u002FNon-Alcoholic Steatohepatitis","Ertu-NASH","Inclusion Criteria:\n\n* Patient able to provide written informed consent\n* Adult males \\& females between 18 to 65 years\n* SGLT2i and insulin naïve patients\n* BMI \\>23 Kg\u002Fm2\n* HbA1C % ≥ 6.5 to 10\n* Documented hepatic steatosis or fatty liver disease on Ultrasound\n* Patient with Type II Diabetes Mellitus\n\nExclusion Criteria:\n\n* History of use of SGLT 2 inhibitors or Glucagon-like peptide (GLP) 1 agonist or insulin; 3 months prior to enrollment in the study.\n* Pioglitazone use in the past 6 months\n* History of vitamin E use (400mg twice daily) 3 months prior to enrollment in the study.\n* History of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study.\n* History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or Cushing's syndrome)\n* History of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and\u002For HIV\n* History of recurrent UTIs and mycotic infection.\n* Severely ill patients (who have high grade fever, sepsis or acute infection)\n* Pregnant woman, lactating woman or planning pregnancy during study duration\n* History of Drug-induced liver disease (e.g. amiodarone, valproate, tamoxifen, methotrexate, steroids (including homeopathic medicines).\n* History of active substance abuse (cannabinoid-derived substances like heroin, cocaine, amphetamines) based on history and\u002For laboratory tests\n* Alcohol intake 10 - 30 g\u002Fday (three drinks per day) within the previous year\n* Active substance abuse such as acetaminophen over-use, hashish, tobacco products, heroin, cocaine or amphetamines.\n* Severe hepatic impairment ( AST \\& ALT levels \\> 3 times upper limit normal",{"count":157,"type":21},164,[91],"Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \\& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)\u002FNon-Alcoholic Steatohepatitis (NASH)",[161,162,163,164,165,166],"Liver Fat","Liver Fibrosis","Glycemic Control","Body Weight Changes","Waist Circumference","Tolerance","2025-03-19",{"date":169,"type":39},"2025-03-21",{"date":171,"type":39},"2023-03-01",{"date":173,"type":21},"2025-12-01",{"name":45,"class":46},1,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100570389","classification-of-adult-onset-diabetes-in-five-subgroups-in-pakistani-population-100570389","NCT06706609","Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population","Inclusion Criteria:\n\n* Patients of both genders whose age of disease onset was older than 16 years\n* Patients newly diagnosed with or previously diagnosed with T2D\n* Able and willing to provide written informed consent and to comply with the study\n\nExclusion Criteria:\n\n* Patients with other medical comorbidities (not a complication of diabetes), such as malignancies.\n* Pregnancy","16 Years",{"count":184,"type":21},394,"This study aims to classify adult-onset diabetes patients into distinct data-driven clusters, such as severe insulin-deficient, severe insulin-resistant, mild obesity-related, and mild age-related diabetes, based on clinical and biochemical characteristics. Using a cross-sectional design, data will be collected from individuals attending outpatient diabetes clinics at tertiary care hospitals in Pakistan. The study will analyze the distribution of metabolic and demographic characteristics within each cluster and assess subgroup-specific risks for diabetic complications. Additionally, the relationship between clustering variables and the risk of complications will be evaluated to enhance the understanding of diabetes heterogeneity and its impact on patient outcomes.",[187,188,189],"Diabetes Mellitus","Diabetes Mellitus, Adult-Onset","Diabetes Mellitus Type 1 and 2","2024-11-22",{"date":192,"type":39},"2024-11-26",{"date":194,"type":21},"2025-02-01",{"date":196,"type":21},"2025-12-31",{"name":45,"class":46},""]